Global Immunotherapy Drugs

Immunotherapy Drugs Comprehensive Study by Type (Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Others), Application (Cancer (Solid Tumor, Malignant), Autoimmune and & Inflammatory Diseases, Infectious Diseases, Others), End User (Hospitals/Clinics, Cancer Research Centers, Others) Players and Region - Global Market Outlook to 2030

Immunotherapy Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Immunotherapy Drugs Market Scope?
Immunotherapy drugs are the drugs that are used for the treatment of cancer that boosts the body's natural defenses to fight cancer. It is made up of white blood cells and organs and tissues of the lymph system. Immunotherapy Drugs market is expected to grow in the future due to the rising incidence of cancer and and increasing demand for recovery drugs. Rising government policies for supporting clinical trials related to drugs making growth in the future.

Influencing Trend:
Upsurging Government Policies for Supporting Clinical Trials

Market Growth Drivers:
Increasing Incidence of Cancer, Rising Prevalence of Chronic Diseases and Rising Geriatric Population

Challenges:
Impending Patent Expiry of Top-Selling Biologics

Restraints:
High Cost of Immunotherapy Treatment and Lack of Awareness about Immunotherapy Drugs

Opportunities:
Rising Opportunities in Emerging Markets such as India, China, etc and Growth in the Demand for Immunotherapy in Cancer Treatment

The Immunotherapy Drugs market study is being classified by Type (Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins and Others), by Application and major geographies with country level break-up.

Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Immunotherapy Drugs market throughout the predicted period.

F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Amgen, Inc. (United States), AbbVie, Inc. (United States), AstraZeneca plc (United Kingdom), Bristol-Myers Squibb (United States) and Eli Lilly and Company (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Juno Therapeutics (United States), Bluebird bio. (United States) and Celldex Therapeutics, Inc (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Immunotherapy Drugs market by Type, Application and Region.

On the basis of geography, the market of Immunotherapy Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies

In September 2017,(MSD) has launched its blockbuster cancer drug ‘Keytruda’ (pembrolizumab) in India around a year after it first received approvals to market it, said persons aware of the development.


Key Target Audience
Pharmaceuticals Manufacturers, Research & Academic Institutions, Hospitals and clinics, Contract Manufacturers and Contract Research Organizations

Immunotherapy Drugs Market Study: Important Years
AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Immunotherapy Drugs Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Immunotherapy Drugs industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines)
  • Checkpoint Inhibitors
  • Interferons Alpha & Beta
  • Interleukins
  • Others
By Application
  • Cancer (Solid Tumor, Malignant)
  • Autoimmune and & Inflammatory Diseases
  • Infectious Diseases
  • Others
By End User
  • Hospitals/Clinics
  • Cancer Research Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Cancer
      • 3.2.2. Rising Prevalence of Chronic Diseases
      • 3.2.3. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Impending Patent Expiry of Top-Selling Biologics
    • 3.4. Market Trends
      • 3.4.1. Upsurging Government Policies for Supporting Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immunotherapy Drugs, by Type, Application, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Immunotherapy Drugs (Value)
      • 5.2.1. Global Immunotherapy Drugs by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines)
        • 5.2.1.3. Checkpoint Inhibitors
        • 5.2.1.4. Interferons Alpha & Beta
        • 5.2.1.5. Interleukins
        • 5.2.1.6. Others
      • 5.2.2. Global Immunotherapy Drugs by: Application (Value)
        • 5.2.2.1. Cancer (Solid Tumor, Malignant)
        • 5.2.2.2. Autoimmune and & Inflammatory Diseases
        • 5.2.2.3. Infectious Diseases
        • 5.2.2.4. Others
      • 5.2.3. Global Immunotherapy Drugs by: End User (Value)
        • 5.2.3.1. Hospitals/Clinics
        • 5.2.3.2. Cancer Research Centers
        • 5.2.3.3. Others
      • 5.2.4. Global Immunotherapy Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Immunotherapy Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bristol-Myers Squibb (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Immunotherapy Drugs Sale, by Type, Application, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Immunotherapy Drugs (Value)
      • 7.2.1. Global Immunotherapy Drugs by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines)
        • 7.2.1.3. Checkpoint Inhibitors
        • 7.2.1.4. Interferons Alpha & Beta
        • 7.2.1.5. Interleukins
        • 7.2.1.6. Others
      • 7.2.2. Global Immunotherapy Drugs by: Application (Value)
        • 7.2.2.1. Cancer (Solid Tumor, Malignant)
        • 7.2.2.2. Autoimmune and & Inflammatory Diseases
        • 7.2.2.3. Infectious Diseases
        • 7.2.2.4. Others
      • 7.2.3. Global Immunotherapy Drugs by: End User (Value)
        • 7.2.3.1. Hospitals/Clinics
        • 7.2.3.2. Cancer Research Centers
        • 7.2.3.3. Others
      • 7.2.4. Global Immunotherapy Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immunotherapy Drugs: by Type(USD Million)
  • Table 2. Immunotherapy Drugs Monoclonal Antibodies , by Region USD Million (2018-2023)
  • Table 3. Immunotherapy Drugs Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines) , by Region USD Million (2018-2023)
  • Table 4. Immunotherapy Drugs Checkpoint Inhibitors , by Region USD Million (2018-2023)
  • Table 5. Immunotherapy Drugs Interferons Alpha & Beta , by Region USD Million (2018-2023)
  • Table 6. Immunotherapy Drugs Interleukins , by Region USD Million (2018-2023)
  • Table 7. Immunotherapy Drugs Others , by Region USD Million (2018-2023)
  • Table 8. Immunotherapy Drugs: by Application(USD Million)
  • Table 9. Immunotherapy Drugs Cancer (Solid Tumor, Malignant) , by Region USD Million (2018-2023)
  • Table 10. Immunotherapy Drugs Autoimmune and & Inflammatory Diseases , by Region USD Million (2018-2023)
  • Table 11. Immunotherapy Drugs Infectious Diseases , by Region USD Million (2018-2023)
  • Table 12. Immunotherapy Drugs Others , by Region USD Million (2018-2023)
  • Table 13. Immunotherapy Drugs: by End User(USD Million)
  • Table 14. Immunotherapy Drugs Hospitals/Clinics , by Region USD Million (2018-2023)
  • Table 15. Immunotherapy Drugs Cancer Research Centers , by Region USD Million (2018-2023)
  • Table 16. Immunotherapy Drugs Others , by Region USD Million (2018-2023)
  • Table 17. South America Immunotherapy Drugs, by Country USD Million (2018-2023)
  • Table 18. South America Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 19. South America Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 20. South America Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 21. Brazil Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 22. Brazil Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 23. Brazil Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 24. Argentina Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 25. Argentina Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 26. Argentina Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 27. Rest of South America Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 30. Asia Pacific Immunotherapy Drugs, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 34. China Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 35. China Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 36. China Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 37. Japan Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 38. Japan Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 39. Japan Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 40. India Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 41. India Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 42. India Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 43. South Korea Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 44. South Korea Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 45. South Korea Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 46. Taiwan Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 47. Taiwan Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 48. Taiwan Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 49. Australia Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 50. Australia Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 51. Australia Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 55. Europe Immunotherapy Drugs, by Country USD Million (2018-2023)
  • Table 56. Europe Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 57. Europe Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 58. Europe Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 59. Germany Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 60. Germany Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 61. Germany Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 62. France Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 63. France Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 64. France Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 65. Italy Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 66. Italy Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 67. Italy Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 68. United Kingdom Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 69. United Kingdom Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 70. United Kingdom Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 71. Netherlands Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 72. Netherlands Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 73. Netherlands Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 74. Rest of Europe Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 75. Rest of Europe Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 76. Rest of Europe Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 77. MEA Immunotherapy Drugs, by Country USD Million (2018-2023)
  • Table 78. MEA Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 79. MEA Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 80. MEA Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 81. Middle East Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 82. Middle East Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 83. Middle East Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 84. Africa Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 85. Africa Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 86. Africa Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 87. North America Immunotherapy Drugs, by Country USD Million (2018-2023)
  • Table 88. North America Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 89. North America Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 90. North America Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 91. United States Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 92. United States Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 93. United States Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 94. Canada Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 95. Canada Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 96. Canada Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 97. Mexico Immunotherapy Drugs, by Type USD Million (2018-2023)
  • Table 98. Mexico Immunotherapy Drugs, by Application USD Million (2018-2023)
  • Table 99. Mexico Immunotherapy Drugs, by End User USD Million (2018-2023)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Immunotherapy Drugs: by Type(USD Million)
  • Table 111. Immunotherapy Drugs Monoclonal Antibodies , by Region USD Million (2025-2030)
  • Table 112. Immunotherapy Drugs Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines) , by Region USD Million (2025-2030)
  • Table 113. Immunotherapy Drugs Checkpoint Inhibitors , by Region USD Million (2025-2030)
  • Table 114. Immunotherapy Drugs Interferons Alpha & Beta , by Region USD Million (2025-2030)
  • Table 115. Immunotherapy Drugs Interleukins , by Region USD Million (2025-2030)
  • Table 116. Immunotherapy Drugs Others , by Region USD Million (2025-2030)
  • Table 117. Immunotherapy Drugs: by Application(USD Million)
  • Table 118. Immunotherapy Drugs Cancer (Solid Tumor, Malignant) , by Region USD Million (2025-2030)
  • Table 119. Immunotherapy Drugs Autoimmune and & Inflammatory Diseases , by Region USD Million (2025-2030)
  • Table 120. Immunotherapy Drugs Infectious Diseases , by Region USD Million (2025-2030)
  • Table 121. Immunotherapy Drugs Others , by Region USD Million (2025-2030)
  • Table 122. Immunotherapy Drugs: by End User(USD Million)
  • Table 123. Immunotherapy Drugs Hospitals/Clinics , by Region USD Million (2025-2030)
  • Table 124. Immunotherapy Drugs Cancer Research Centers , by Region USD Million (2025-2030)
  • Table 125. Immunotherapy Drugs Others , by Region USD Million (2025-2030)
  • Table 126. South America Immunotherapy Drugs, by Country USD Million (2025-2030)
  • Table 127. South America Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 128. South America Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 129. South America Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 130. Brazil Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 131. Brazil Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 132. Brazil Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 133. Argentina Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 134. Argentina Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 135. Argentina Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 136. Rest of South America Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 137. Rest of South America Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 138. Rest of South America Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 139. Asia Pacific Immunotherapy Drugs, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 141. Asia Pacific Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 142. Asia Pacific Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 143. China Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 144. China Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 145. China Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 146. Japan Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 147. Japan Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 148. Japan Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 149. India Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 150. India Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 151. India Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 152. South Korea Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 153. South Korea Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 154. South Korea Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 155. Taiwan Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 156. Taiwan Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 157. Taiwan Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 158. Australia Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 159. Australia Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 160. Australia Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 164. Europe Immunotherapy Drugs, by Country USD Million (2025-2030)
  • Table 165. Europe Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 166. Europe Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 167. Europe Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 168. Germany Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 169. Germany Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 170. Germany Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 171. France Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 172. France Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 173. France Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 174. Italy Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 175. Italy Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 176. Italy Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 177. United Kingdom Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 178. United Kingdom Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 179. United Kingdom Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 180. Netherlands Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 181. Netherlands Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 182. Netherlands Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 183. Rest of Europe Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 184. Rest of Europe Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 185. Rest of Europe Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 186. MEA Immunotherapy Drugs, by Country USD Million (2025-2030)
  • Table 187. MEA Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 188. MEA Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 189. MEA Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 190. Middle East Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 191. Middle East Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 192. Middle East Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 193. Africa Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 194. Africa Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 195. Africa Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 196. North America Immunotherapy Drugs, by Country USD Million (2025-2030)
  • Table 197. North America Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 198. North America Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 199. North America Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 200. United States Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 201. United States Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 202. United States Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 203. Canada Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 204. Canada Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 205. Canada Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 206. Mexico Immunotherapy Drugs, by Type USD Million (2025-2030)
  • Table 207. Mexico Immunotherapy Drugs, by Application USD Million (2025-2030)
  • Table 208. Mexico Immunotherapy Drugs, by End User USD Million (2025-2030)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immunotherapy Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Immunotherapy Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Immunotherapy Drugs: by End User USD Million (2018-2023)
  • Figure 7. South America Immunotherapy Drugs Share (%), by Country
  • Figure 8. Asia Pacific Immunotherapy Drugs Share (%), by Country
  • Figure 9. Europe Immunotherapy Drugs Share (%), by Country
  • Figure 10. MEA Immunotherapy Drugs Share (%), by Country
  • Figure 11. North America Immunotherapy Drugs Share (%), by Country
  • Figure 12. Global Immunotherapy Drugs share by Players 2023 (%)
  • Figure 13. Global Immunotherapy Drugs share by Players (Top 3) 2023(%)
  • Figure 14. Global Immunotherapy Drugs share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 18. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 22. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 23. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 24. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 26. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. AbbVie, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 34. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 36. Global Immunotherapy Drugs: by Type USD Million (2025-2030)
  • Figure 37. Global Immunotherapy Drugs: by Application USD Million (2025-2030)
  • Figure 38. Global Immunotherapy Drugs: by End User USD Million (2025-2030)
  • Figure 39. South America Immunotherapy Drugs Share (%), by Country
  • Figure 40. Asia Pacific Immunotherapy Drugs Share (%), by Country
  • Figure 41. Europe Immunotherapy Drugs Share (%), by Country
  • Figure 42. MEA Immunotherapy Drugs Share (%), by Country
  • Figure 43. North America Immunotherapy Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Novartis International AG (Switzerland)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline (United Kingdom)
  • Amgen, Inc. (United States)
  • AbbVie, Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly and Company (United States)
Additional players considered in the study are as follows:
Juno Therapeutics (United States) , Bluebird bio. (United States) , Celldex Therapeutics, Inc (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 243 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Immunotherapy Drugs Quantitative research analysis
Global Immunotherapy Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Immunotherapy Drugs market are F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Amgen, Inc. (United States), AbbVie, Inc. (United States), AstraZeneca plc (United Kingdom), Bristol-Myers Squibb (United States) and Eli Lilly and Company (United States).
In this highly competitive & fast evolving Immunotherapy Drugs industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Cancer (Solid Tumor, Malignant), Autoimmune and & Inflammatory Diseases, Infectious Diseases and Others are the potential customers of Immunotherapy Drugs industry.
The Global Immunotherapy Drugs market is expected to see a growth of 20.3% during projected year 2023 to 2030.

Know More About Global Immunotherapy Drugs Report?

Have a Query? Click Here

Other Related Reports

Allyl Methacrylate Comprehensive Study by Type (Allyl Methacrylate 98%, Allyl Methacrylate 99.5%), Application (Paints& Coatings, Floor Polishes, Dentistry Materials, Other), Distribution Channel (Di...
$ 3350
Cat Allergy Comprehensive Study by Type (Antihistamine, Decongestants Medication), Application (Hospital, Ambulatory Surgical Centers), Test Type (Scratch test, Intradermal test) Players and Region -...
$ 3500
Protease Inhibitors Comprehensive Study by Application (Commodity Protease Inhibitor, Research Tool Protease Inhibitor, Protease Inhibitor Drugs), Mechanism of Action (Serine Protease Inhibitors, Cys...
$ 3750
Diabetic Gastroparesis Treatment Comprehensive Study by Type (Drugs, Surgical Treatment Products), Application (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce), By T...
$ 3750
Antibacterial Washcloth Comprehensive Study by Type (Mix type, Cotton, Bamboo Extract, Linen, Other Materials), Application (Patient and peri-care, Bathing, General Cleaning, Housekeeping) Players an...
$ 3500
Hypereosinophilic Syndrome Drug Comprehensive Study by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), Application (Research Center, Hospital, Clinic) Players and...
$ 3500